IN2014KN02993A - - Google Patents
Info
- Publication number
- IN2014KN02993A IN2014KN02993A IN2993KON2014A IN2014KN02993A IN 2014KN02993 A IN2014KN02993 A IN 2014KN02993A IN 2993KON2014 A IN2993KON2014 A IN 2993KON2014A IN 2014KN02993 A IN2014KN02993 A IN 2014KN02993A
- Authority
- IN
- India
- Prior art keywords
- compounds
- modulators
- making
- methods
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Abstract
This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261672455P | 2012-07-17 | 2012-07-17 | |
| US201361748874P | 2013-01-04 | 2013-01-04 | |
| PCT/IB2013/001530 WO2014013309A1 (en) | 2012-07-17 | 2013-07-15 | Indolecarbonitriles as selective androgen receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014KN02993A true IN2014KN02993A (en) | 2015-05-08 |
Family
ID=49117887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2993KON2014 IN2014KN02993A (en) | 2012-07-17 | 2013-07-15 |
Country Status (39)
| Country | Link |
|---|---|
| US (5) | US8957104B2 (en) |
| EP (1) | EP2875013B1 (en) |
| JP (1) | JP6106746B2 (en) |
| KR (1) | KR102127939B1 (en) |
| CN (1) | CN104619693B (en) |
| AR (1) | AR091770A1 (en) |
| AU (1) | AU2013291721B2 (en) |
| BR (1) | BR112015000940B1 (en) |
| CA (1) | CA2879104C (en) |
| CL (1) | CL2015000119A1 (en) |
| CO (1) | CO7240378A2 (en) |
| CR (1) | CR20150008A (en) |
| CY (1) | CY1120064T1 (en) |
| DK (1) | DK2875013T3 (en) |
| DO (1) | DOP2015000004A (en) |
| EA (1) | EA026371B8 (en) |
| ES (1) | ES2657912T3 (en) |
| HK (1) | HK1208867A1 (en) |
| HR (1) | HRP20180061T1 (en) |
| HU (1) | HUE036238T2 (en) |
| IL (1) | IL236448A (en) |
| IN (1) | IN2014KN02993A (en) |
| JO (1) | JO3384B1 (en) |
| LT (1) | LT2875013T (en) |
| ME (1) | ME02996B (en) |
| MX (1) | MX349943B (en) |
| MY (2) | MY198512A (en) |
| NZ (1) | NZ703129A (en) |
| PE (1) | PE20150371A1 (en) |
| PH (1) | PH12015500104B1 (en) |
| PL (1) | PL2875013T3 (en) |
| PT (1) | PT2875013T (en) |
| RS (1) | RS56810B1 (en) |
| SG (1) | SG11201408493WA (en) |
| SI (1) | SI2875013T1 (en) |
| TW (1) | TWI574946B (en) |
| UY (1) | UY34911A (en) |
| WO (1) | WO2014013309A1 (en) |
| ZA (1) | ZA201500096B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10155099B2 (en) | 2009-09-21 | 2018-12-18 | Cook Regentec Llc | Method for infusing stem cells |
| MY198512A (en) | 2012-07-17 | 2023-09-01 | Glaxosmithkline Ip No 2 Ltd | Indolecarbonitriles as selective androgen receptor modulators |
| US9902694B2 (en) * | 2014-01-21 | 2018-02-27 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED | Crystalline forms |
| KR20190077607A (en) * | 2014-10-16 | 2019-07-03 | 지티엑스, 인코포레이티드 | METHODS OF TREATING UROLOGICAL DISORDERS USING SARMs |
| CN105130872B (en) * | 2015-08-25 | 2018-01-30 | 江西师范大学 | Preparation method of 3-trifluoromethyl substituted indole |
| CN110437125B (en) * | 2019-09-06 | 2021-03-12 | 苏州旺山旺水生物医药有限公司 | Preparation method of Tezacaftor intermediate II |
| WO2022204235A1 (en) * | 2021-03-23 | 2022-09-29 | Nido Biosciences, Inc. | Bicyclic compounds as androgen receptor modulators |
| CN115010574B (en) * | 2022-06-06 | 2024-01-05 | 爱斯特（成都）生物制药股份有限公司 | Synthesis method of 1-bromo-2-chloro-4-fluoro-2-iodobenzene |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2322161A1 (en) | 1998-02-25 | 1999-09-02 | Yibin Xiang | Inhibitors of phospholipase enzymes |
| EA005852B1 (en) * | 1998-06-19 | 2005-06-30 | Пфайзер Продактс Инк. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
| US6576265B1 (en) | 1999-12-22 | 2003-06-10 | Acell, Inc. | Tissue regenerative composition, method of making, and method of use thereof |
| CN100475789C (en) | 2002-05-24 | 2009-04-08 | 拜尔农作物科学股份公司 | Process for the preparation of thioalkylamine derivatives |
| US7517899B2 (en) | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
| CN1960973A (en) * | 2004-03-30 | 2007-05-09 | 惠氏公司 | 1-(1h-indol-1-yl)-3-(4-methylpiperazin-1-yl)-1-phenyl propan-2-ol derivatives and related compounds as modulators of the norepinephrine(NE) and the serotonine(5-HT) activity and the monoamine reuptake |
| AU2005243238B2 (en) | 2004-05-03 | 2011-11-10 | Janssen Pharmaceutica N.V. | Novel indole derivatives as selective androgen receptor modulators (SARMS) |
| ES2371170T3 (en) | 2004-05-03 | 2011-12-28 | Janssen Pharmaceutica Nv | BENZOFURAN DERIVATIVES SELECTIVE COMMOMODULATORS OF ANDROGEN RECEPTORS (MSRA). |
| CN1980917B (en) | 2004-05-03 | 2014-02-12 | 詹森药业有限公司 | Novel indole derivatives as selective androgen receptor modulators (SARMS) |
| EP1756054B1 (en) * | 2004-06-01 | 2010-03-31 | F.Hoffmann-La Roche Ag | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitor |
| KR100987870B1 (en) * | 2005-07-29 | 2010-10-13 | 화이자 프로덕츠 인코포레이티드 | Pyrrolo[2,3-d]pyrimidine derivatives, their intermediates and synthesis |
| GB0526246D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| CN101426778A (en) * | 2006-03-15 | 2009-05-06 | 惠氏公司 | N-substituted-azacyclylamines as histamine-3 antagonists |
| CA2645731A1 (en) * | 2006-03-15 | 2007-09-27 | Wyeth | N-substituted-azacyclylamines as histamine-3 antagonists |
| WO2008042571A2 (en) | 2006-09-29 | 2008-04-10 | Smithkline Beecham Corporation | Substituted indole compounds |
| PT2384326E (en) * | 2008-08-20 | 2014-06-09 | Zoetis Llc | Pyrrolo[2,3-d]pyrimidine compounds |
| US9095572B2 (en) | 2009-01-09 | 2015-08-04 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| WO2010118287A1 (en) * | 2009-04-10 | 2010-10-14 | Radius Health, Inc. | Selective androgen receptor modulators |
| KR20120083452A (en) * | 2009-10-15 | 2012-07-25 | 화이자 인코포레이티드 | Pyrrolo[2,3-d]pyrimidine compounds |
| WO2011075334A1 (en) * | 2009-12-18 | 2011-06-23 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
| US8933113B2 (en) * | 2011-01-20 | 2015-01-13 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
| PL2796460T3 (en) * | 2011-12-21 | 2018-12-31 | Jiangsu Hengrui Medicine Co. Ltd. | Pyrrole six-membered heteroaryl ring derivative, preparation method therefor, and medicinal uses thereof |
| MY198512A (en) * | 2012-07-17 | 2023-09-01 | Glaxosmithkline Ip No 2 Ltd | Indolecarbonitriles as selective androgen receptor modulators |
| US9902694B2 (en) * | 2014-01-21 | 2018-02-27 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED | Crystalline forms |
-
2013
- 2013-07-15 MY MYPI2018001949A patent/MY198512A/en unknown
- 2013-07-15 ME MEP-2018-16A patent/ME02996B/en unknown
- 2013-07-15 PE PE2015000039A patent/PE20150371A1/en active IP Right Grant
- 2013-07-15 IN IN2993KON2014 patent/IN2014KN02993A/en unknown
- 2013-07-15 UY UY0001034911A patent/UY34911A/en not_active Application Discontinuation
- 2013-07-15 NZ NZ703129A patent/NZ703129A/en unknown
- 2013-07-15 PL PL13758975T patent/PL2875013T3/en unknown
- 2013-07-15 MY MYPI2015000121A patent/MY173845A/en unknown
- 2013-07-15 WO PCT/IB2013/001530 patent/WO2014013309A1/en active Application Filing
- 2013-07-15 TW TW102125297A patent/TWI574946B/en active
- 2013-07-15 EP EP13758975.0A patent/EP2875013B1/en active Active
- 2013-07-15 LT LTEP13758975.0T patent/LT2875013T/en unknown
- 2013-07-15 CA CA2879104A patent/CA2879104C/en active Active
- 2013-07-15 MX MX2015000825A patent/MX349943B/en active IP Right Grant
- 2013-07-15 EA EA201492237A patent/EA026371B8/en not_active IP Right Cessation
- 2013-07-15 HU HUE13758975A patent/HUE036238T2/en unknown
- 2013-07-15 CN CN201380048232.8A patent/CN104619693B/en active Active
- 2013-07-15 AR ARP130102513A patent/AR091770A1/en active IP Right Grant
- 2013-07-15 DK DK13758975.0T patent/DK2875013T3/en active
- 2013-07-15 JO JOP/2013/0214A patent/JO3384B1/en active
- 2013-07-15 AU AU2013291721A patent/AU2013291721B2/en active Active
- 2013-07-15 JP JP2015522180A patent/JP6106746B2/en active Active
- 2013-07-15 US US13/941,911 patent/US8957104B2/en active Active
- 2013-07-15 BR BR112015000940-9A patent/BR112015000940B1/en active IP Right Grant
- 2013-07-15 KR KR1020157003959A patent/KR102127939B1/en active IP Right Grant
- 2013-07-15 SG SG11201408493WA patent/SG11201408493WA/en unknown
- 2013-07-15 RS RS20180119A patent/RS56810B1/en unknown
- 2013-07-15 SI SI201330945T patent/SI2875013T1/en unknown
- 2013-07-15 ES ES13758975.0T patent/ES2657912T3/en active Active
- 2013-07-15 PT PT137589750T patent/PT2875013T/en unknown
-
2014
- 2014-11-20 US US14/549,034 patent/US9533948B2/en active Active
- 2014-12-23 CO CO14282153A patent/CO7240378A2/en unknown
- 2014-12-25 IL IL236448A patent/IL236448A/en active IP Right Grant
-
2015
- 2015-01-07 ZA ZA2015/00096A patent/ZA201500096B/en unknown
- 2015-01-08 DO DO2015000004A patent/DOP2015000004A/en unknown
- 2015-01-09 CR CR20150008A patent/CR20150008A/en unknown
- 2015-01-14 PH PH12015500104A patent/PH12015500104B1/en unknown
- 2015-01-16 CL CL2015000119A patent/CL2015000119A1/en unknown
- 2015-09-30 HK HK15109640.8A patent/HK1208867A1/en unknown
-
2016
- 2016-11-22 US US15/358,458 patent/US10196353B2/en active Active
-
2018
- 2018-01-15 HR HRP20180061TT patent/HRP20180061T1/en unknown
- 2018-02-13 CY CY20181100173T patent/CY1120064T1/en unknown
- 2018-12-20 US US16/226,763 patent/US10710963B2/en active Active
-
2020
- 2020-05-12 US US16/872,949 patent/US11299457B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273567A (en) | Derivatives of (3a,sp,7a)-3,7-dioxy-23-amino-24-norcholane as fxr/tgrs modulators | |
| PH12018500718A1 (en) | Compounds useful as modulators of trpm8 | |
| PH12016500968B1 (en) | Octahydro fused azadecalin glucocorticoid receptor modulators | |
| PH12014502132A1 (en) | Anti-lgr5 antibodies and immunoconjugates | |
| PH12014502601A1 (en) | ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | |
| MX2021009309A (en) | Modulation of complement activity. | |
| IN2014KN02993A (en) | ||
| GB201017345D0 (en) | Receptor antagonists | |
| MY172739A (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
| MX2022000053A (en) | Modulators of sestrin-gator2 interaction and uses thereof. | |
| UA109931C2 (en) | PIRIMIDINCYCLOHEXYL MODULATORS OF GLUCOCORTICOID RECEPTORS | |
| PH12015501059A1 (en) | Anti-hemagglutinin antibodies and methods of use | |
| IN2015DN00127A (en) | ||
| IN2014DN05885A (en) | ||
| JO3755B1 (en) | Testosterone formulations | |
| IN2015DN01688A (en) | ||
| IN2014DN09450A (en) | ||
| TN2014000136A1 (en) | Selective androgen receptor modulators | |
| IN2013MU00848A (en) | ||
| EP3364957A4 (en) | Improved synthesis of honokiol | |
| MX2016000219A (en) | Dihydroxyphenyl neurotransmitter compounds, compositions and methods. | |
| EP2994542A4 (en) | Compositions for ovarian cancer assessment having improved specificity | |
| IN2013MU01113A (en) | ||
| IN2014DN10209A (en) | ||
| EP3074890A4 (en) | Generating resources for support of online services |